Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025."Amid a difficult operating environment impa ...

FRANKLIN LAKES, N.J., April 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 13, 2025 at 1:00 pm Eastern Time.The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the l ...

Industry Overview - The Medical sector is experiencing a continued recovery in sales, with earnings increasing year over year by 4.7% on 9.4% higher revenues, although inflationary pressures and supply chain challenges persist [1][2] - The first-quarter earnings for the Medical sector are expected to improve by 35%, while sales are projected to increase by 7.8%, compared to the previous quarter's earnings growth of 13.4% and revenue growth of 9.4% [3] Medical Device Industry Insights - The medical device industry began 2025 with robust growth, driven by sustained demand for advanced healthcare solutions and the normalization of elective procedures, with the global market projected to reach $1.3 trillion by 2029 [4] - Challenges such as semiconductor shortages and workforce shortages in AI and robotics are impacting production and innovation [5] - Trade tensions, particularly U.S.-China tariffs, have increased operational costs for medical device manufacturers, with 75% of U.S.-marketed medical devices manufactured abroad [6] Company Performance Expectations - Becton Dickinson is expected to report strong second-quarter results, with a projected revenue growth of 16.3% year over year in its Medical division, although a slight dip of 1.3% is anticipated in the Life Sciences segment [8] - Cardinal Health is expected to show steady performance in its Pharmaceutical and Specialty Solutions segment, supported by strategic acquisitions, despite the impact of a key customer contract expiration [10] - Baxter International is projected to report moderate growth, with an estimated 6.6% sales growth in its Medical Products & Therapies segment, aided by operational recovery [11] - DexCom's outlook remains promising, with a full-year revenue guidance of $4.6 billion, driven by expanded U.S. prescriber coverage and strong international performance [12] - Stryker Corporation is expected to show strong growth across multiple segments, with projected U.S. and international sales reaching $4.74 billion and $1.59 billion, respectively [13]

Becton Dickinson and Company (BDX) , popularly known as BD, is scheduled to report second-quarter fiscal 2025 results on May 1, before market open.In the last reported quarter, the company’s earnings per share (EPS) of $3.43 surpassed the Zacks Consensus Estimate by 15.1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 7.3%, on average. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s che ...

Phasix™ ST Umbilical Hernia Patch Leverages Same Surgical Technique as Permanent Mesh Procedures FRANKLIN LAKES, N.J., April 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasix™ ST Umbilical Hernia Patch, the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias.   BD launche ...

Becton, Dickinson and Company (BDX) , popularly known as BD, launched a new advanced hemodynamic monitoring platform, HemoSphere Alta, yesterday. The platform is equipped with predictive, artificial intelligence (AI)-based algorithms that will likely aid clinicians to address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.The HemoSphere Alta platform, which is BD's most advanced hemodynamic monitoring technology currently available, i ...

HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical SituationsFRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure insta ...

Group 1 - The article emphasizes the importance of long-term investing over market timing, highlighting that successful investing requires patience and a focus on consistent growth rather than short-term fluctuations [1] - The author shares personal experiences in managing an IRA and building a portfolio, aiming to inspire other DIY investors, particularly those on a limited budget [2] - The investment strategy primarily focuses on dividend-paying stocks with a history of consistent earnings and dividend growth, aligning with goals for retirement savings and funding education [2] Group 2 - The author holds long positions in a diverse range of companies, including AAPL, MSFT, and XOM, indicating a broad investment strategy across various sectors [3] - The article does not serve as professional investment advice, and readers are encouraged to conduct their own due diligence before making investment decisions [4][5]

Core Viewpoint - Becton, Dickinson and Company (BDX) is considering divesting its Life Sciences division to focus on becoming a pure-play medtech company, with discussions already initiated with potential buyers [1][4][10]. Group 1: Strategic Shift and Divestment Plans - The Life Sciences unit, which includes the Biosciences and Integrated Diagnostic Solutions businesses, generated significant revenues in 2024, but BDX plans to retain the specimen management segment [2]. - The divestment could streamline BD's portfolio, allowing for focused investment in high-growth medtech areas and potentially delivering tax-efficient returns [4][10]. - The board's unanimous approval of the Life Sciences separation indicates strong internal alignment with this strategy, influenced by activist investor Starboard Value [10]. Group 2: Market Reaction and Stock Performance - BDX shares have declined 9.3% since the Financial Times report on April 1, primarily due to a broader market downturn [3]. - Year-to-date, BDX's shares have lost 9.6%, while the industry has grown by 3.4%, and the S&P 500 has decreased by 14.1% [4]. Group 3: Potential Buyers and Deal Structures - Strategic interest in the Life Sciences business is strong, with Thermo Fisher and Danaher among the potential buyers, focusing on complementary parts of the business [5]. - BD is considering a share swap deal with smaller diagnostics firms, allowing BD shareholders to receive a majority stake in a new entity, thus avoiding capital gains tax [6][8]. Group 4: Future Outlook - BD is expected to announce further plans for the Life Sciences unit by mid-2025, with a targeted transaction close by the end of next year [11].

FRANKLIN LAKES, N.J., April 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 1, 2025 to discuss the Company's financial results for its second quarter of fiscal year 2025, which ended on March 31, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors ...